The Role of Gut Microbiota in Heart Failure and Pre-Heart Failure With Preserved Ejection Fraction

Recruiting

Brief Summary: Gut microbiota play an important role in normal cardiovascular function and pathophysiology of cardiovascular diseases. Patients with heart failure (HF) have substantial hemodynamic changes which lead to intestinal hypoperfusion and congestion and eventually change gut morphology, permeability, function and composition of gut microbiota and cause translocation of microbial and endotoxins into the blood stream. Additionally, metabolites derived from gut microbiota modulate the pathophysiology of HF. Patients with HF have intestinal overgrowth of pathogenic bacteria and increased gut permeability. Accumulating evidence demonstrates that antibiotic treatment benefits patients with acute coronary syndromes and reduces the incidence of ischemic cardiovascular events. Taking the strong association of gut microbiota with HF into account, it is reasonable to speculate that gut microbiota could contribute to the progression of pre-HF with preserved ejection fraction (pre-HFpEF) to HF with preserved ejection fraction (HFpEF). Pre-HFpEF remains poorly understood, yet has high prevalence and a significantly high risk for death in comparison to patient without pre-HFpEF. We hypothesize that altered gut microbiota is involved in the initiation and establishment of HF and pre-HFpEF.

Detailed Description: The research study will initially enroll 50 subjects without HF as normal controls,120 subjects with history of HF and 50 subjects with pre-HFpEF to characterize gut microbiota. The subjects will provide blood samples and a stool sample.

Recruitment & Eligibility

Inclusion Criteria

Competent and willing to provide consent
Control subjects with normal heart function
Subjects with history of HF
Subjects with impaired ventricular relaxation and/or elevated left ventricular end diastolic pressure measured by echocardiography and/or catheterization, yet has not had HF clinical presentations

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
Normal control	Stool Sample	The subjects in the normal heart function group will provide a blood sample and stool sample.
Normal control	Blood Sample	The subjects in the normal heart function group will provide a blood sample and stool sample.
heart failure	Blood Sample	The subjects in history of heart failure group will provide a blood sample and stool sample.
heart failure	Stool Sample	The subjects in history of heart failure group will provide a blood sample and stool sample.
pre-HFpEF	Stool Sample	The subjects in history of diastolic dysfunction but not had heart failure clinical presentations group will provide a blood sample and stool sample.
pre-HFpEF	Blood Sample	The subjects in history of diastolic dysfunction but not had heart failure clinical presentations group will provide a blood sample and stool sample.

Primary Outcome Measures

Name	Time	Method
Stool sample for fecal microbiota between the groups	Day 1	Stool samples will be collected to compare the fecal microbiota of subjects with normal, diastolic heart dysfunction before heart failure developed and heart failure.

Secondary Outcome Measures

Name	Time	Method
Blood samples for inflammatory cytokines between the groups	Day 1	Blood samples will be used to compare difference in inflammatory cytokines including Interleukin-1 (IL-1), 6, 17 between groups using ELISA kits.
Blood samples for inflammatory cells between the groups	Day 1	Blood samples will be used for difference in progenitor/inflammatory cells between the groups.
Blood samples for SAA between the groups	Day 1	Blood samples will be used to compare difference in serum amyloid (SAA) a between groups using ELISA kits.

Locations (1): Cardiovascular Clinic at UF Health
🇺🇸
Gainesville, Florida, United States

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial